Male hormonal contraceptives: A potentially patentable and profitable product

Expert Opinion on Therapeutic Patents

Volumn 15, Issue 12, 2005, Pages 1727-1737

  Cornia, Paul B ^a   Anawalt, Bradley D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Androgen; Gonadotropin releasing hormone analogue; Gonadotropins; Male contraception; Progestogen; Spermatogenesis; Testosterone

Indexed keywords

ABARELIX; CASTOR OIL; CETRORELIX; CYPROTERONE ACETATE; DESOGESTREL; DIENOGEST; DROSPIRENONE; ETONOGESTREL; FINASTERIDE; GESTAGEN; GONADORELIN; GONADOTROPIN; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEVONORGESTREL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALE CONTRACEPTIVE AGENT; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SHORT ACTING DRUG; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE; TRESTOLONE; UNINDEXED DRUG; VEGETABLE OIL;

ACNE; AZOOSPERMIA; BODY WEIGHT DISORDER; CLINICAL TRIAL; CONDOM; CONTRACEPTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FEASIBILITY STUDY; HUMAN; LIVER TOXICITY; MALE; OUTCOMES RESEARCH; PREGNANCY; PROSTATE CANCER; REVIEW; STRUCTURE ANALYSIS; TRANSDERMAL PATCH; VASECTOMY; WORLD HEALTH ORGANIZATION;

EID: 30344439101     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.15.12.1727     Document Type: Review

References (69)

1. UNITED NATIONS FAMILY PLANNING ASSOCIATION: Report of the International Conference on Population Development. New York, United Nations (1994).
2. MCLACHLAN RI, O'DONNEL L, MEACHEM SJ et al.: Identification of specific sites of hormonal regulation of spermatogenesis in rats, monkeys, and man. Recent Prog. Horm. Res. (2002) 57:149-179.
3. WORLD HEALTH ORGANIZATION TASK FORCE ON METHODS FOR THE REGULATION OF MALE FERTILITY: Contraceptive efficacy of testosterone-induced azoospermia by testosterone enanthate in normal men. Lancet (1990) 336:995-999.
4. WORLD HEALTH ORGANIZATION TASK FORCE ON METHODS FOR THE REGULATION OF MALE FERTILITY: Contraceptive efficacy of testosterone-induced azoospermia or oligozoospermia by testosterone enanthate in normal men. Fertil. Steril. (1996) 65:821-829.
5. HANDELSMAN DJ, FARLEY TM, PEREGOUDOV A, WAITES GM: Factors in nonuniform induction of azoospermia by restosterone enanthate in men. Fertil. Steril. (1995) 63:125-133.
6. VON ECKARDSTEIN A, BUCHTER D, NIESCHLAG E: Successful treatment of male hypogonadism with testosterone undecanoate (TU) in extended intervals of 12 weeks. VIIth International Congress of Andrology. Montreal, Canada (2001).
7. ZHANG GY, GU YQ, WANG XH, CUI Y, BREMNER WJ: A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. J. Androl. (1998) 19:761-768.
8. BEHRE HM, ABSRAGEN K, OETTEL M, HUBLER D, NIESCHLAG E: Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: Phase I studies. Eur. J. Endocrinol. (1999) 140:414-419.
9. ANDERSON RA, ZHU H, CHENG L, BAIRD DT: Investigation of a novel preparation of testosterone decanoate in men: pharmacokinetics and spermatogenic suppression with etonorgestrel implants. Contraception (2002) 66:357-364.
10. HAY CJ, GRADY BM, ZITZMANN M et al.: A multicenter Phase IIb study of a novel combination of intramuscular androgen (testosterone decanoate) and oral progestogen (etonogestrel) for male hormonal contraception. J. Clin. Endocrinol. Metab. (2005) 90:2042-2049.
11. HANDELSMAN DJ, CONWAY AJ, BOYLAN LM: Pharmacotherapy and pharmacokinetics of testosterone pellets in man. J. Clin. Endocrinol. Metab. (1990) 71:216-22.
12. GU YQ, WANG XH, XU D et al.: A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. J. Clin. Endocrinol. Metab. (2003) 88:562-568.
13. GU YQ, TONG QS, MA DZ et al.: Male hormonal contraception: effects of injections of testosterone undecanoate and depot medroxyprogesterone acetate at eight-week intervals in Chinese men. J. Clin. Endocrinol. Metab. (2004) 89:2254-2262.
14. HEINEMANN K, SAAD F, WIESEMES M, WHITE S, HEINEMANN L: Attitudes toward male fertility control: results of a multinational survey on four continents. Hum. Reprod. (2005) 20:549-556.
15. BUCHTER D, VON ECKARDSTEIN S, VON ECKARDSTEIN A et al.: Clinical trial of transdermal testosterone and oral levonorgestrel for male contraception. J. Clin. Endocrinol. Metab. (1999) 84:1244-1249.
16. GONZALO ITG, SWERDLOFF RS, NELSON AL et al.: Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone. J. Clin. Endocrinol. Metab. (2002) 87:3562-3572.
17. WANG C, CUNNINGHAM G, DOBS A et al.: Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J. Clin. Endocrinol. Metab. (2004) 89:2085-2098.
18. BAGATELL CJ, BREMNER WJ: Androgens in men - uses and abuses. N. Engl. J. Med. (1996) 334:707-714.
19. MERIGGIOLA MC, BREMNER WJ, CONSTANTINO A, PAVANI A, CAPELLI M, FLAMIGNI C: An oral regimen of cyproterone acetate and testosterone undecanoate for spermatogenic suppression in men. Fertil. Steril. (1997) 68:844-850.
20. AMORY JK, BREMNER WJ: Oral testosterone in oil plus dutasteride in men: a pharmacokinetic study. J. Clin. Endocrinol. Metab. (2005) 90:2610-2617.
21. HELLER CG, LAIDLAW WM, HARVEY HT, NELSON WO: Effects of progestational compounds on the reproductive processes of the human male. Ann. NY Acad. Sci. (1958) 71:649-665.
22. BEBB RA, ANAWALT BD, CHRISTENSEN RB et al.: Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than restosterone alone: a promising male contraceptive approach. J. Clin. Endocrinol. Metab. (1996) 81:3018-3023.
23. MERIGGIOLA MC, FARLEY TM, MBIZVO MT: A review of androgen-progestin combinations for male contraception. J. Androl. (2003) 24:466-483.
24. WORLD HEALTH ORGANIZATION TASK FORCE ON METHODS FOR THE REGULATION OF MALE FERTILITY: Comparison of two androgens plus depot-medroxyprogestrone acetate for suppression to azoospermia in Indonesian men. Fertil. Steril. (1993) 60:1062-1068.
25. TURNER L, CONWAY AJ, JIMENEZ M et al.: Contraceptive efficacy of a depot progestin and androgen combination in men. J. Clin. Endocrinol. Metab. (2003) 88:4659-4667.
26. KAMISCHKE A, VENHERM S, PLODGER D, VON ECKARDSTEIN S, NIESCHLAG E: Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception. J. Clin. Endocrinol. Metab. (2001) 86:303-309.
27. KAMISCHKE A, HEUERMANN T, KRUGER K et al.: An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations. J. Clin. Endocrinol. Metab. (2002) 87:530-539.
28. MERIGGIOLA MC, CONSTANTINO A, SAAD F et al.: Norethisterone enanthate plus testosterone undecanoate for male contraception: effects of various injection intervals on spermatogenesis, reproductive hormones, testis and prostate. J. Clin. Endocrinol. Metab. (2005) 90:2005-2014.
29. ANDERSON RA, KINNIBURGH D, BAIRD DT: Suppression of spermatogenesis by etonogestrel implants with depot testosterone: potential for long-acting male contraception. J. Clin. Endocrinol. Metab. (2002) 87:3640-3649.
30. BRADY BM, WALTON M, HOLLOW N, KICMAN AT, BAIRD DT, ANDERSON RA: Depot testosterone with etonorgestrel implants result in induction of azoospermia in all men for long-term contraception. Hum. Reprod. (2004) 19:2658-2667.
31. ANAWALT BD, BEBB RA, BREMNER WJ, MATSUMOTO AM: A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations. J. Androl. (1999) 20:407-413.
32. ANAWALT BD, AMORY JK, HERBST KL et al.: Intramuscular testosterone enanthate plus very low dosage oral levonorgestrel suppresses spermatogenesis without causing weight gain in normal young men: a randomized clinical trial. J. Androl. (2005) 26:405-413.
33. WU FCW, BALASUBRAMANIAN R, MULDERS TM, COELINGH-BENNICK HJ: Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism. J. Clin. Endocrinol. Metab. (1999) 84:112-122.
34. ANAWALT BD, HERBST KL, MATSUMOTO AM, MULDERS TM, COELINGH-BENNICK HJ, BREMNER WJ: Desogestrel plus testosterone effectively suppresses spermatogenesis but also causes modest weight gain and high-density lipoprotein suppression. Fertil. Steril. (2000) 74:707-714.
35. KINNIBURGH D, ZHU H, CHENG L, KICMAN AT, BAIRD DT, ANDERSON RA: Oral desogestrel with testosterone pellets induces consistent suppression of spermatogenesis to azoospermia in both Caucasian and Chinese men. Hum. Reprod. (2002) 17:1490-1501.
36. ZHANG FP, PAKARAINEN T, POUTANEN M, TOPPARI J, HUHTANIEMI I: The low gonadotropin-independent constitutive production of testicular testosterone is sufficient to maintain spermatogenesis. Proc. Natl. Acad. Sci. USA (2003) 100:13692-13697.
37. MERIGGIOLA MC, CONSTANTINO A, BREMNER WJ, MORSELLI-LABATE AM: Higher testosterone dose impairs sperm suppression induced by a combined androgen-progestin regimen. J. Androl. (2002) 23:684-689.
38. MERIGGIOLA MC, BREMNER WJ, PAULSEN C et al.: A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive. J. Clin. Endocrinol. Metab. (1996) 81:3018-3023.
39. MERIGGIOLA MC, BREMNER WJ, CONSTANTINO A, DI CINTIO, G, FLAMIGNI C: Low dose cyproterone actetate and testosterone enanthate for contraception in men. Hum. Reprod. (1998) 13:1225-1229.
40. MERIGGIOLA MC, CONSTANTINO A, CERPOLINI S et al.: Testosterone undecanoate maintains spermatogenic suppression induced by cyproterone acetate plus testosterone undecanoate in normal men. J. Clin. Endocrinol. Metab. (2003) 88:5818-5826.
41. SWERDLOFF RS, BAGATELL CJ, WANG C et al.: Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone. J. Clin. Endocrinol. Metab. (1998) 83:3527-3533.
42. SITRUK-WARE R: Pharmacolgical profile of progestins. Maturitas. (2004) 47:277-283.
43. KEAM SJ, WAGSTAFF AJ: Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive. Treat. Endocrinol. (2003) 2:49-70.
44. MERIGGIOLA MC, BREMNER WJ, CONSTANTINO A et al.: Twenty-one day administration of dienogest reversibly suppresses gonadotropins and testosterone in normal men. J. Clin. Endocrinol. Metab. (2002) 87:2107-2113.
45. CUMMINGS DE, BREMNER WJ: Prospects for new hormonal male contraceptives. Endocrinol. Metab. Clin. North Am. (1994) 23:893-922.
46. PAVLOU SN, BREWER K, FARLEY MG et al.: Combined administration of a gonadotropin-releasing antagonist and testosterone in men induces reversible azoospermia without loss of libido. J. Clin. Endocrinol. Metab. (1991) 73:1360-1369.
47. TOM L, BHASIN S, SALAMEH W et al.: Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate. J. Clin. Endocrinol. Metab. (1992) 75:476-483.
48. BAGATELL CJ, MATSUMOTO AM, CHRISTENSEN RB, RIVIER JE, BREMNER WJ: Comparison of a gonadotropin-releasing antagonist plus testosterone (T) versus testosterone alone as potential male contraceptive regimens. J. Clin. Endocrinol. Metab. (1993) 77:427-432.
49. HERBST KL, ANAWALT BD, AMORY JK, BREMNER WJ: Acyline: the first study in humans of a potent, gonadotropin-releasing hormone antagonist. J. Clin. Endocrinol. Metab. (2002) 87:3215-3220.
50. CHO N, HARADA M, IMEDA T et al.: Discovery of a novel, potent, and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH) receptor. J. Med. Chem. (1998) 41:4190-4195.
51. BESECKE L, DIAZ G, SEGRETI T et al.: Pharmacological and endocrine characterization of A-19840, an orally active GnRH antagonist in intact and castrate male rat models. Drug Dev. Res. (2001) 52:485-491.
52. HAMMAN LG, HIGUCHI RI, ZHI L et al.: Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective, androgen receptor antagonists derived from 1,2-dihydropyridono [5,6g]-quinolines. J. Med. Chem. (1998) 41:623-639.
53. HAMMAN LG, MANI NS, DAVIS RL et al.: Discovery of a potent orally active, nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6-(trifluormethyl)-8-pyridino[5,6g]-quinoline (LG121071). J. Med. Chem. (1999) 84:3459-3462.
54. ANDERSON RA, WALLACE AM, SATTAR N, KUMAR N, SUNDARAM K: Evidence for tissue selectivity of the synthetic androgen 7-α-methyl-19-nortestosterone in hypogonadal men. J. Clin. Endocrinol. Metab. (2003) 88:2784-2793.
55. VON ECKARDSTEIN S, NOW G, BRACHE V et al.: A clinical trial of 7-α-methyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men. J. Clin. Endocrinol. Metab. (2003) 88:5232-5239.
56. CHEN J, HWANG DJ, BOHL CE, MILLER DD, DALTON JT: A selective androgen receptor modulator for hormonal male contraception. J. Pharmacol. Exp. Ther. (2005) 312:546-553.
57. ANDERSON R, WALLACE A, WU FC: Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive. III. Higher 5α-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone. J. Clin. Endocrinol. Metab. (1996) 81:902-908.
58. THOMPSON IM, GOODMAN PJ, TANGEN CM et al.: The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. (2003) 349:215-224.
59. MCLACHLAN RI, MCDONALD J, RUSHFORD D et al.: Efficacy and acceptability of testosterone implants, alone or in combination with a 5α-reductase inhibitor, for male hormonal contraception. Fertil. Steril. (2000) 62:73-78.
60. KINNIBURGH D, ANDERSON R, BAIRD D: Suppression of spermatogenesis with desogestrel pellets is not enhanced by the addition of finasteride. J. Androl. (2001) 22:88-95.
61. O'DONNELL L, STANTON PG, WREFORD NG, ROBERTSON DM, MCLACHLAN RI: Inhibition of 5α-reductase activity impairs the testosterone-dependent restoration of spermiogenesis in adult rats. Endocrinology (1996) 137:2703-2710.
62. O'DONNELL L, PRATIS K, STANTON PG, ROBERTSON DM, MCLACHLAN RI: Testosterone-dependent restoration of spermiogenesis in adult rats is impaired by a 5-α-reductase inhibitor. J. Androl. (1999) 20:109-117.
63. ROEHRBORN CG, BOYLE P, NICKEL JC, HOEFNER K, ANDRIOLE G: Efficacy and safety of a dual inhibitor of 5-α-reductase types I and II (dutasteride) in men with benign prostatic hypertrophy. Urology (2002) 60:434-441.
64. MATTHIESSON KL, AMORY JK, BERGER R, UGONI A, MCLACHLAN RI, BREMNER WJ: Novel male hormonal contraceptive combinations: the hormonal and spermatogenic effects of testosterone and levonorgestrel combined with a 5-α-reductase inhibitor or gonadotropin-releasing hormone antagonist. J. Clin. Endocrinol. Metab. (2005) 90:91-97.
65. O'DONNELL L, ROBERTSON KM, JONES ME, SIMPSON ER: Estrogen and spermatogenesis. Endocr. Rev. (2001) 22:289-318.
66. DE RONDE W, POLS HAP, VAN LEEUWEN JP, DE JONG FH: The importance of oestrogens in males. Clin. Endocrinol. (2003) 58:529-542.
67. HANDELSMAN DJ, WISHART S, CONWAY AJ: Oestradiol enhances testosterone-induced suppression of human spermatogenesis. Hum. Reprod. (2000) 15:672-679.
68. MARTIN CW, ANDERSON RA, CHENG L et al.: Potential implications of hormonal male contraception: cross-cultural implications for development of novel preparations. Hum. Reprod. (2000) 15:637-645.
69. GLASIER AF, ANAKWE R, EVERINGTON D et al.: Would women trust their partners to use a male pill? Hum. Reprod. (2000) 15:646-649.